XML 18 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Revenues:      
Revenue under collaborative research and development arrangements $ 28,407,388 $ 6,490,747 $ 26,876,533
Revenue under collaborative research and development arrangements with affiliated entities 765,828 1,400,594 779,167
Grants and miscellaneous revenue 10,474,539 27,136,457 12,916,411
Grants and miscellaneous revenue from affiliated entity 2,572,331 340,563 0
Total revenues 42,220,086 35,368,361 40,572,111
Operating expenses:      
Research and development 98,572,618 88,712,035 57,791,923
General and administrative 28,290,369 23,892,263 18,063,890
Gain on sale of assets (1,000,000) (1,000,000) (1,000,000)
Total operating expenses 125,862,987 111,604,298 74,855,813
Loss from operations (83,642,901) (76,235,937) (34,283,702)
Other income (expense):      
Interest and other income, net 1,612,974 1,257,257 305,071
Change in fair value of common stock warrants 806,819 127,554 177,561
Gain (loss) on investment in affiliated entity (6,982,664) 1,110,787 2,600,467
Net loss before income tax benefit (88,205,772) (73,740,339) (31,200,603)
Income tax benefit 0 0 2,097,766
Net loss (88,205,772) (73,740,339) (29,102,837)
Net income attributable to non-controlling interest 0 0 (84,769)
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (88,205,772) $ (73,740,339) $ (29,187,606)
Net loss per common share attributable to Inovio Pharmaceuticals, Inc. stockholders      
Basic ($ per share) $ (1.08) $ (1.01) $ (0.43)
Diluted ($ per share) $ (1.09) $ (1.01) $ (0.44)
Weighted average number of common shares outstanding used in per share calculations:      
Basic (shares) 81,777,493 73,214,766 68,198,142
Diluted (shares) 81,918,022 73,214,766 68,365,265